精確搜索結(jié)果
- Products
- 內(nèi)容類型
- Analysis Platform
- 語言
- Publication Date
1 - 20 共 22 條結(jié)果
應(yīng)用的篩選條件
AACR 2025 poster: Chronic anti-CD3/CD28 stimulation during cell expansion generates exhausted T cells with a distinct metabolic and cytotoxic phenotype
In this study, we present a robust approach to monitor and analyze the bystander effect of Antibody-Drug Conjugates in real-time using live-cell imaging andimpedance measurements with the Agilent xCELLigence RTCA eSight system.
The eSight can be used to study cytotoxicity kinetics of lymphocytes invading a deregulated extracellular matrix present in solid tumors.
There is a need for functional potency assays that can be used to rapidly test the efficacy of different immunotherapy approaches, including but not limited tosmall molecules, biologics, cell therapies, or combinations of these agents
we demonstrated consistent production of CAR T-cells using the functionally closed and automated cell manufacturing Lonza Cocoon platform, using a novelcombination of cell analysis parameters obtained from an Agilent xCELLigence RTCA system, a...
Multiparametric real-time automated readouts using simultaneous cellular impedance and live cell imaging.
This editorial showcases Agilent solutions for metabolic modulation enhancing CAR T-cell activation, persistence, and serial killing for improved cancer immunotherapy
SPS 2024. Poster 112-D. To explore the potential on/off target immune-mediated toxicity of EpCAM-CD3 BiTE antibodies, a panel of human primary cells representing different tissues was exposed to EpCAM BiTE in the presence of PBMCs and monitored in...
CAR-TCR 2024 Poster. We demonstrated the successful production of CAR T-cells using the Lonza Cocoon system. Additionally, CAR T-cell in-process analyses and critical process parameters were evaluated using the combination of a flow cytometer, a...
In this application note, Antibody Analytics (Motherwell, UK) integrates IndEx-2, an advanced in vitro cell-based platform engineered to modulate the expression of one or two target antigens across a range of biologically relevant levels, with the...
This editorial will discuss the potency assays available for cellular immunotherapies, the regulatory criteria they must meet, and the challenges faced in measuring immune cell cytotoxicity.
This application note describes a novel real-time co-culture assay using RTCA eSight for interrogating NK92 immune cell invasion and cytotoxicity and migratory kinetic profiles based on ECM and effects of TME.
This application note evaluates the Agilent xCELLigence RTCA eSight as a tool to monitor BiTE antibody-mediated cancer cell lysis.
Although cell therapies have shown great promise in clinical studies, challenges with the large scale manufacturing of these therapies still need to be addressed.
xCELLigence Immunotherapy IMT Assay (anti-CD9) Tethering Kit and Sample Kit Protocol
xCELLigence Immunotherapy IMT Assay (anti-CD40) Tethering Kit and Sample Kit Protocol
xCELLigence Immunotherapy IMT Assay (anti-CD29) Tethering Kit and Sample Kit Protocol
xCELLigence Immunotherapy IMT Assay (anti-CD71) Tethering Kit and Sample Kit Protocol
xCELLigence Immunotherapy IMT Assay (anti-CD19) Tethering Kit and Sample Kit Protocol
Using the Agilent xCELLigence RTCA eSight to continuously monitor CAR T cell-mediatedkilling of cancer cells over the course of multiplae days.